Stockscreener 앱 받기
17.37
1.16%
0.20
시간 외 거래:
17.28
-0.09
-0.52%
전일 마감가:
$17.17
열려 있는:
$17.13
하루 거래량:
14.32M
Relative Volume:
1.24
시가총액:
$20.23B
수익:
$14.57B
순이익/손실:
$-296.50M
주가수익비율:
-67.07
EPS:
-0.259
순현금흐름:
$1.64B
1주 성능:
+8.90%
1개월 성능:
+25.60%
6개월 성능:
+59.21%
1년 성능:
+97.61%
1일 변동 폭
$16.96
$17.39
1주일 범위
$16.36
$17.53
52주 변동 폭
$8.19
$17.53
비아트리스 Stock (VTRS) Company Profile
명칭
Viatris Inc
전화
(724) 514-1465
주소
1000 MYLAN BOULEVARD, CANONSBURG
Compare VTRS vs TAK, TEVA, HLN, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
17.37 | 20.00B | 14.57B | -296.50M | 1.64B | -0.259 |
TAK
Takeda Pharmaceutical Co Adr
|
16.64 | 51.87B | 29.85B | 776.90M | 4.35B | 0.2408 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.25 | 41.70B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.02 | 40.34B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
74.34 | 32.26B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
579.54 | 24.69B | 3.17B | 1.29B | 1.01B | 27.09 |
비아트리스 Stock (VTRS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-09 | 업그레이드 | UBS | Neutral → Buy |
| 2026-01-16 | 업그레이드 | Argus | Hold → Buy |
| 2025-12-09 | 개시 | Barclays | Overweight |
| 2025-10-15 | 개시 | Truist | Buy |
| 2025-06-06 | 개시 | Goldman | Neutral |
| 2024-07-19 | 재개 | Jefferies | Buy |
| 2023-10-23 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2023-06-23 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2023-04-24 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2023-02-17 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-27 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-11-10 | 업그레이드 | UBS | Sell → Neutral |
| 2022-11-08 | 업그레이드 | Piper Sandler | Underweight → Neutral |
| 2022-10-21 | 재개 | Jefferies | Hold |
| 2022-06-14 | 개시 | UBS | Sell |
| 2022-05-10 | 다운그레이드 | Piper Sandler | Neutral → Underweight |
| 2022-03-01 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-03-01 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2021-06-15 | 개시 | Citigroup | Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2021-03-08 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-03-02 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-02-26 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2021-01-05 | 개시 | Argus | Hold |
| 2020-12-14 | 개시 | Bernstein | Mkt Perform |
모두보기
비아트리스 주식(VTRS)의 최신 뉴스
Fed. Circ. Won't Save Actelion's Suit Over Hypertension Drug - Law360
Viatris Inc. stock rises Wednesday, outperforms market - MarketWatch
Earnings call transcript: Viatris Q1 2026 beats EPS forecast, stock rises - Investing.com
Viatris Hypertension Drug Doesn’t Copy J&J Patents, Court Says - Bloomberg Law News
Why Viatris (VTRS) is a Top Value Stock for the Long-Term - sharewise.com
Viatris CFO leaving Canonsburg pharma giant - MSN
HHS officials considered banning SSRI antidepressantsreport - MSN
Viatris (VTRS) Is Up 10.6% After Q1 Beat, CFO Change And Outlook ReaffirmationWhat's Changed - simplywall.st
Viatris Inc. stock rises Tuesday, outperforms market - MarketWatch
Transcript : Viatris Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 08 - marketscreener.com
Why Viatris (VTRS) is a Top Growth Stock for the Long-Term - Yahoo Finance
Viatris: From Cost Story To Pipeline-Driven Re-Rating (Rating Upgrade) (NASDAQ:VTRS) - Seeking Alpha
VTRS Q1 Deep Dive: China Strength, R&D Pipeline, and Execution Drive Outperformance - Yahoo Finance
Viatris Inc. stock falls Monday, underperforms market - MarketWatch
Viatris gears up to report Q1 earnings: What's in the cards? - MSN
Presbyopia Market to Witness Accelerated Growth at a CAGR of 4.9% During the Forecast Period (2026–2036) Supported by Expanding Treatment Landscape | DelveInsight - GlobeNewswire Inc.
Viatris: The Cigar Butt Got Smoked, But I'm Holding The Rating (NASDAQ:VTRS) - Seeking Alpha
UBS Adjusts Viatris Price Target to $23 From $20 - Moomoo
Viatris Inc. (VTRS) Stock Analysis: Exploring the Healthcare Giant’s Valuation and Dividend Yield - DirectorsTalk Interviews
Viatris Announces Second Quarter 2024 Dividend - Quantisnow
Viatris Q1 2026 earnings preview: Caution remains around ongoing turnaround - MSN
Viatris Inc. stock rises Thursday, outperforms market - MSN
Viatris Inc. (NASDAQ:VTRS) Q1 2026 Earnings Call Transcript - Insider Monkey
Viatris Earnings Call Highlights Profits, Pipeline Momentum - The Globe and Mail
Viatris Inc. stock falls Friday, underperforms market - MarketWatch
Research Alert: CFRA Keeps Hold Opinion On Shares Of Viatris Inc. - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
TBPH Q1 Earnings Beat Amid Strategic Restructuring & Pipeline Hurdle - TradingView
Truist Financial Maintains Viatris(VTRS.US) With Buy Rating, Announces Target Price $20 - Moomoo
Hypercholesterolemia Treatment Market is expected to Hit US$ - openPR.com
Viatris: Q1 Earnings Snapshot - theheraldreview.com
Viatris Inc. Stock 12‑Month Price Target Raised to $17.25, Implies 1% Downside - TradingView
Viatris to Present at the Bank of America Securities 2026 Healthcare Conference - BioSpace
Viatris (VTRS) Heavy FY 2025 Losses Keep Bullish Turnaround Narratives Under Pressure - Sahm
5-Day Rally Sends Viatris Stock Up 16% - Trefis
Viatris Stock Rockets 16% With 5-Day Winning Streak - Trefis
Viatris stock hits 52-week high at $16.63 By Investing.com - Investing.com Nigeria
Viatris Q1 2026 Earnings Call Transcript - MarketBeat
Viatris Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Viatris (VTRS) Jumps As Targets Rise And Pipeline Delivers - timothysykes.com
Viatris to Present at the Bank of America Securities 2026 Healthcare Conference – Company Announcement - Financial Times
Viatris Earnings: Stable Base Business and Pipeline Progression Mark a Solid Start to 2026 - Morningstar
Viatris (NASDAQ: VTRS) returns to profit as sales rise in Q1 2026 - Stock Titan
Viatris (VTRS) Q1 2026 Earnings Call Transcript - Fortune
Viatris Q1 EPS Beats Estimates, Revenues up 8% Driven by Greater China - sharewise.com
Viatris signals 2026 cash deployment of more than $2.5B while expecting Greater China mid- to high-single-digit growth - MSN
Viatris Releases Q1 2026 Financial Results - AlphaStreet
Viatris (VTRS) Q4 2025 Earnings Call Transcript - Fortune
After Kicking Off 2026 Solidly, Viatris Looks to New Launches and Cost Savings for Long-term Growth - Morningstar
Viatris’ Turnaround Story Is Paying Off in the Stock - Finimize
Viatris Q1 2026 slides: earnings beat drives shares higher - Investing.com
비아트리스 (VTRS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.54%
0.38%
자본화:
|
볼륨(24시간):